The Manufacturers Life Insurance Company Invests $76,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

The Manufacturers Life Insurance Company bought a new stake in Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 29,371 shares of the company’s stock, valued at approximately $76,000.

Other hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. acquired a new position in Aquestive Therapeutics in the 2nd quarter valued at approximately $27,000. SG Americas Securities LLC bought a new stake in shares of Aquestive Therapeutics during the first quarter valued at approximately $54,000. Lazard Asset Management LLC raised its stake in shares of Aquestive Therapeutics by 115.5% in the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock valued at $124,000 after purchasing an additional 15,601 shares in the last quarter. Financial Advocates Investment Management raised its stake in shares of Aquestive Therapeutics by 70.0% in the second quarter. Financial Advocates Investment Management now owns 34,000 shares of the company’s stock valued at $88,000 after purchasing an additional 14,000 shares in the last quarter. Finally, PFG Investments LLC lifted its position in Aquestive Therapeutics by 22.9% in the second quarter. PFG Investments LLC now owns 59,000 shares of the company’s stock worth $153,000 after purchasing an additional 11,000 shares during the period. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Stock Up 2.2 %

Shares of Aquestive Therapeutics stock opened at $5.03 on Monday. Aquestive Therapeutics, Inc. has a 12-month low of $1.36 and a 12-month high of $6.23. The stock has a market capitalization of $457.93 million, a P/E ratio of -11.98 and a beta of 2.85. The company has a 50-day simple moving average of $4.63 and a 200 day simple moving average of $3.71.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.08. The firm had revenue of $20.10 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter last year, the firm posted ($0.10) EPS. On average, equities analysts anticipate that Aquestive Therapeutics, Inc. will post -0.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AQST has been the topic of several analyst reports. Leerink Partners reissued an “outperform” rating and issued a $12.00 price target (up previously from $10.00) on shares of Aquestive Therapeutics in a report on Monday, September 30th. JMP Securities reiterated a “market outperform” rating and set a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright increased their price target on shares of Aquestive Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $8.67.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.